Screener
Oruka Therapeutics, Inc. ORKA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (1,304) | 2,317 |
| Operating lease liability | (125) | (21) |
| Related party accounts payable and other current liabilities | 2,995 | (5,205) |
| Net cash used in operating activities | (23,578) | (20,869) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (73) | (13) |
| Purchases of marketable securities | (90,834) | (44,290) |
| Proceeds from maturities of marketable securities | 76,470 | 87,169 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s operating cash flow?
- Oruka Therapeutics, Inc. (ORKA) reported operating cash flow of -$23.58M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Oruka Therapeutics, Inc.'s operating cash flow decreased by 13.0% year-over-year, from -$20.87M to -$23.58M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s operating cash flow has grown at a 47.3% compound annual growth rate (CAGR), from -$18.76M to -$88.21M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Oruka Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude